Carol Lynch
Global Head of Biopharmaceuticals, Sandoz
Meet Carol Lynch
Judges praised Carol for her role in the biosimilars industry and in the launch of the first US biosimilar. She joined Sandoz in 2014 and is focused on leading efforts in the development, manufacture and commercialization of biosimilars. In February 2016, she was elected as Chair of Medicines for Europe’s (formerly the EGA’s) European Biosimilars Group, where she will be working to improve stakeholder awareness and understanding of, and confidence in biosimilars and advocating for policies that support the growth of the biosimilars industry.